Matrix Metalloproteinases: Drug Targets for Myocardial Infarction

Author(s): Andriy Yabluchanskiy, Yaojun Li, Robert J. Chilton, Merry L. Lindsey

Journal Name: Current Drug Targets

Volume 14 , Issue 3 , 2013

Become EABM
Become Reviewer
Call for Editor


Myocardial infarction (MI) remains a major cause of morbidity and mortality worldwide. Rapid advances in the treatment of acute MI have significantly improved short-term outcomes in patients, due in large part to successes in preventing myocardial cell death and limiting infarct area during the time of ischemia and subsequent reperfusion. Matrix metalloproteases (MMPs) play key roles in post-MI cardiac remodeling and in the development of adverse outcomes. This review highlights the importance of MMPs in the injury and remodeling response of the left ventricle and also discusses their potential as therapeutic targets Additional pre-clinical and clinical research is needed to further investigate and understand the cardioprotective effects of MMPs inhibitors.

Keywords: Extracellular matrix, left ventricle, left ventricle remodeling, matrix metalloproteinases, myocardial infarction, Macrophage Infiltration, Polymorphonuclear Leukocyte Infiltration, Myofibroblast Activation, tissue inhibitors of metalloproteinases (TIMPs), Collagen

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Published on: 27 January, 2013
Page: [276 - 286]
Pages: 11
DOI: 10.2174/1389450111314030002
Price: $65

Article Metrics

PDF: 12